Literature DB >> 17095590

Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis.

Tim D Hewitson1, Ishanee Mookerjee, Rosemary Masterson, Chongxin Zhao, Geoffrey W Tregear, Gavin J Becker, Chrishan S Samuel.   

Abstract

Relaxin is a naturally occurring regulator of collagen turnover. In this study, we determined the role of endogenous relaxin in the pathogenesis of primary tubulointerstitial fibrosis after unilateral ureteric obstruction (UUO). Four- to 6-wk-old relaxin (RLX) gene-knockout (RLX(-/-)) and age-matched wild-type (RLX(+/+)) mice, with equivalent baseline collagen levels, were subjected to UUO. Obstructed and contralateral kidneys were collected at d 0, 3, and 10 after surgery and analyzed for changes in inflammatory and fibrosis-related markers. UUO was associated with a progressive increase in fibrosis in all obstructed, but not contralateral kidneys. The increase in total collagen (hydroxyproline analysis) was associated with more alpha-smooth muscle actin (alpha-SMA) staining (myofibroblasts) and interstitial collagen sub-types (SDS-PAGE; types I, III, and V), whereas gelatin zymography demonstrated increased expression of matrix metalloproteinase-2 after surgery. By d 10 after UUO, there was a 5-fold decrease in RLX mRNA expression (quantitative RT-PCR) in RLX(+/+) animals. Total collagen and alpha-SMA expression were significantly greater in the obstructed kidneys of RLX(-/-) mice 3 d after UUO (both P < 0.05 vs. RLX(+/+) D3 after UUO), but comparable to that in RLX(+/+) animals 10 d after UUO. Administration of recombinant H2 relaxin to RLX(-/-) mice 4 d before UUO ameliorated the increase in collagen and alpha-SMA expression (both P < 0.05 vs. untreated RLX(-/-) mice) by d 3 after UUO. Expression of monocyte chemoattractant protein-1 and macrophage infiltration (inflammation) in addition to that of matrix metalloproteinases was unaffected by genotype after UUO. These combined data demonstrate that endogenous RLX acts as a modulating factor in tubulointerstitial fibrosis, a hallmark of progressive renal disease. This is likely to be via direct effects on renal myofibroblast function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17095590     DOI: 10.1210/en.2006-0814

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

Review 1.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 2.  Renal fibrosis: novel insights into mechanisms and therapeutic targets.

Authors:  Peter Boor; Tammo Ostendorf; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2010-09-14       Impact factor: 28.314

Review 3.  Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases.

Authors:  Jeffrey L Barnes; Yves Gorin
Journal:  Kidney Int       Date:  2011-02-09       Impact factor: 10.612

Review 4.  Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease.

Authors:  Yifang Li; Sharon D Ricardo; Chrishan S Samuel
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

5.  Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury.

Authors:  Yuben Moodley; Daniel Atienza; Ursula Manuelpillai; Chrishan S Samuel; Jorge Tchongue; Sivakami Ilancheran; Richard Boyd; Alan Trounson
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

Review 6.  Relaxin and its role in the development and treatment of fibrosis.

Authors:  Robert G Bennett
Journal:  Transl Res       Date:  2009-04-22       Impact factor: 7.012

Review 7.  Cyclic nucleotide signalling in kidney fibrosis.

Authors:  Elisabeth Schinner; Veronika Wetzl; Jens Schlossmann
Journal:  Int J Mol Sci       Date:  2015-01-22       Impact factor: 5.923

Review 8.  The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.

Authors:  Ting-Yun Chen; Xiaoyun Li; Ching-Hsia Hung; Harinath Bahudhanapati; Jiangning Tan; Daniel J Kass; Yingze Zhang
Journal:  Mol Genet Genomic Med       Date:  2020-02-26       Impact factor: 2.183

9.  Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling.

Authors:  Lucia Formigli; Avio-Maria Perna; Elisabetta Meacci; Lorenzo Cinci; Martina Margheri; Silvia Nistri; Alessia Tani; Josh Silvertown; Giovanni Orlandini; Cristina Porciani; Sandra Zecchi-Orlandini; Jeffrey Medin; Daniele Bani
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

10.  Involvement of Cyclic Guanosine Monophosphate-Dependent Protein Kinase I in Renal Antifibrotic Effects of Serelaxin.

Authors:  Veronika Wetzl; Elisabeth Schinner; Frieder Kees; Franz Hofmann; Lothar Faerber; Jens Schlossmann
Journal:  Front Pharmacol       Date:  2016-07-12       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.